NV-5138
Phase 2- Indications
- Treatment-resistant depression, Cognitive impairment
Company intelligence / Profile preview
Navitor Pharmaceuticals
Cambridge, Massachusetts, United Stateszoominfo.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 2
01
Overview
Navitor Pharmaceuticals develops small molecule therapeutics that selectively modulate the mTORC1 pathway. Their lead asset NV‑5138 has reached Phase 2 clinical trials for treatment-resistant depression. Another candidate, NV‑20494, targets autosomal dominant polycystic kidney disease and has entered early clinical development. The company’s proprietary platform enables targeting nutrient signaling pathways implicated in a range of chronic and rare conditions.
- Therapeutic areas
- PsychiatryMetabolic DisordersNephrologyRheumatologyImmunologyRare DiseasesNeurology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Supernus Pharmaceuticals – Development and option agreement for orally active mTORC1 activator NV‑5138.
Beyond the preview
Go deeper on Navitor Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Navitor Pharmaceuticals.